Sigyn Therapeutics Bolsters Board with Experienced Medtech Investor Michael Ryan

Sigyn Therapeutics has expanded its Board of Directors with the appointment of Michael Ryan, an accomplished executive and investor with extensive experience in the life sciences and technology sectors. Ryan's addition to the board is expected to provide strategic insights and investment expertise as the company advances its blood purification technologies.

With a background in mechanical and industrial engineering from University College Dublin, Ryan brings a wealth of medical technology experience. As a Founding Director of Irrus Investments, he has overseen significant investments in early-stage life science and technology companies, with the syndicate deploying over $50 million across 40 companies in multiple countries.

Ryan's professional history includes leadership roles in notable medical technology companies. He served as CEO of Sedana Medical until its initial public offering on the Nasdaq First North stock exchange in Stockholm, and previously led Artema Medical AB through its successful acquisition by Datascope Corporation.

Sigyn Therapeutics CEO Jim Joyce highlighted Ryan's potential contributions, emphasizing his expertise in supporting innovative medical technologies. Ryan expressed enthusiasm about joining the board, particularly noting the company's promising approach to addressing complex global health challenges through advanced blood purification technologies.

The company's lead product, Sigyn Therapy, demonstrates potential in treating critical medical conditions by reducing viral pathogens, bacterial toxins, and pro-inflammatory cytokines in human blood plasma. Its applications could potentially impact treatment protocols for life-threatening viruses, antibiotic-resistant infections, endotoxemia, and sepsis.

Ryan's appointment coincides with Sigyn Therapeutics' ongoing development of multiple therapeutic platforms, including ImmunePrepTM, ChemoPrepTM, and ChemoPureTM, which aim to enhance cancer treatment delivery and reduce therapeutic toxicity.

The strategic addition of Michael Ryan to the board signals continued growth and potential for Sigyn Therapeutics in developing innovative medical technologies that could significantly impact patient care and treatment outcomes.